Ermeza Solution
Product Images NDC 49502-378

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ermeza (NDC 49502-378). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levothyroxine Sodium Structural Formula (Image 01)

FDA Label Image

Mcg Dosage To mL Conversion (Image 02)

This text provides information on dosage measurement equivalence between milliliters and micrograms, stating that a dosage of 30 mcg is equal to a dosage of 30 mL.*

FDA Label Image

Instructions For Use Figure A (Image 03)

The text describes Figure A, which is a diagram showing two oral syringes, a 5mL syringe, and a 10mL syringe. The syringes have a plunger and a barrel and are used to measure the prescribed dose of medication. The text advises using the graduation markings to measure accurately. Therefore, the text serves as a guide for properly using an oral syringe while administering medication.*

FDA Label Image

Instructions For Use Figure B (Image 04)

FDA Label Image

Instructions For Use Figure C (Image 05)

FDA Label Image

Instructions For Use Figure D (Image 06)

FDA Label Image

Mcg Dosage To mL Conversion (Image 07)

This is a simple conversion formula indicating that the dosage in micrograms (mcg) is equivalent to the dosage in milliliters (mL) and the specific conversion value is not given.*

FDA Label Image

Ermeza Oral Solution 150 Mcg/5 mL Carton Label (Image 08)

Ermeza is an oral solution of Levothyroxine sodium prescribed for oral administration only. The usual dosage information is available on the accompanying prescribing information. The medication should be stored and dispensed only in the original bottle and protected from light. The solution contains Levothyroxine sodium, USP 150 mcg/ 5mL (30 mcg/mL) and is available in 5mL and 10mL oral syringes. It is manufactured for Hylan Specialty LP and the trademark is owned by Viatris Inc. The medication should be used within 90 days of opening the bottle and kept out of the reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.